Healthcare provider profile · identity verified

Catalina Negulescu, MD

Internal Medicine · BATON ROUGE, LA · NPI 1700862521

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	392	41
Amlodipine Besylate	Amlodipine Besylate	333	42
Gabapentin	Gabapentin	216	26
Furosemide	Furosemide	209	37
Levothyroxine Sodium	Levothyroxine Sodium	202	21
Losartan Potassium	Losartan Potassium	194	18
Clopidogrel	Clopidogrel Bisulfate	167	22
Lisinopril	Lisinopril	142	16
Carvedilol	Carvedilol	130	18
Donepezil Hcl	Donepezil Hcl	126	11
Trazodone Hcl	Trazodone Hcl	126	15
Escitalopram Oxalate	Escitalopram Oxalate	123	12
Sertraline Hcl	Sertraline Hcl	123	13
Eliquis	Apixaban	114	16
Metformin Hcl	Metformin Hcl	107	12
Metoprolol Succinate	Metoprolol Succinate	104	17
Memantine Hcl	Memantine Hcl	102	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	101	13
Tamsulosin Hcl	Tamsulosin Hcl	101	15
Omeprazole	Omeprazole	98	suppressed
Duloxetine Hcl	Duloxetine Hcl	95	suppressed
Potassium Chloride	Potassium Chloride	95	21
Pantoprazole Sodium	Pantoprazole Sodium	85	20
Risperidone	Risperidone	77	suppressed
Famotidine	Famotidine	76	suppressed
Jardiance	Empagliflozin	74	suppressed
Rexulti	Brexpiprazole	68	suppressed
Ondansetron Hcl	Ondansetron Hcl	62	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	61	suppressed
Hydralazine Hcl	Hydralazine Hcl	57	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	55	14
Ropinirole Hcl	Ropinirole Hcl	55	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	54	suppressed
Tramadol Hcl	Tramadol Hcl	54	11
Baclofen	Baclofen	53	suppressed
Mirtazapine	Mirtazapine	51	suppressed
Spironolactone	Spironolactone	45	suppressed
Levetiracetam	Levetiracetam	42	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	37	suppressed
Latanoprost	Latanoprost	37	suppressed
Xarelto	Rivaroxaban	37	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	36	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	36	suppressed
Tizanidine Hcl	Tizanidine Hcl	36	suppressed
Finasteride	Finasteride	34	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	33	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	32	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	32	suppressed
Lactulose	Lactulose	30	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	30	suppressed
Torsemide	Torsemide	30	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	29	suppressed
Restasis	Cyclosporine	29	suppressed
Diltiazem Hcl	Diltiazem Hcl	27	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	26	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	25	13
Cilostazol	Cilostazol	25	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	25	suppressed
Methocarbamol	Methocarbamol	25	suppressed
Ranolazine Er	Ranolazine	25	suppressed
Bupropion Xl	Bupropion Hcl	24	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	23	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	23	18
Alendronate Sodium	Alendronate Sodium	22	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	22	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	22	17
Anastrozole	Anastrozole	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Divalproex Sodium Er	Divalproex Sodium	21	suppressed
Fluticasone Propionate	Fluticasone Propionate	21	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	21	suppressed
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Levofloxacin	Levofloxacin	20	11
Olmesartan Medoxomil	Olmesartan Medoxomil	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Timolol Maleate	Timolol Maleate	20	suppressed
Memantine Hcl Er	Memantine Hcl	19	suppressed
Prezcobix	Darunavir/Cobicistat	19	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	18	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	18	suppressed
Fluconazole	Fluconazole	18	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	15
Carbamazepine	Carbamazepine	16	suppressed
Lithium Carbonate	Lithium Carbonate	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	16	suppressed
Bumetanide	Bumetanide	15	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	15	suppressed
Estradiol	Estradiol	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Digoxin	Digoxin	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	14	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	14	suppressed
Allopurinol	Allopurinol	13	suppressed
Clonidine	Clonidine	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Prednisone	Prednisone	13	13
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	suppressed
Entresto	Sacubitril/Valsartan	12	suppressed
Methimazole	Methimazole	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Valsartan	Valsartan	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Glipizide	Glipizide	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Prednisolone Acetate	Prednisolone Acetate	11	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error